Chapter 91: Northstar
Sterling announced the largest transaction in its history at eight the next morning.
I was still in Helena's library when my phone filled with alerts. The company had signed a merger framework with Northstar Health at an announced value of seven billion dollars. Conrad appeared in the press photograph beside Northstar's chair. Celeste stood between them beneath a screen carrying both companies' names.
Nathan stood one step behind her.
The release called the deal a union of Sterling's research platform and Northstar's international development network. It described AURORA-9 as the central asset supporting the valuation.
It did not mention a suspended license.
It did not mention the independent inventor determination.
It did not mention that Helena Research Trust owned the underlying patents.
"They are trying to make size sound like title," Rhea said over the phone.
I opened the public transaction summary. The first twelve pages were celebration. The thirteenth contained the warranties.
Sterling represented that it owned or validly controlled all rights necessary to develop, license, market, and transfer the AURORA-9 platform without restriction material to the transaction.
The language was broader than the confidential notice we had seen weeks earlier. That notice had identified no counterparty and disclosed no complete terms. This document named Northstar, named the price, and made complete AURORA rights a condition of the deal.
"Can they say that while the license is suspended?" I asked.
"They can print it," Rhea replied. "Whether they can support it is a different question."
The Trust had suspended Sterling's platform license after the attribution dispute and safety concerns. That action had not transferred the license to Mercer Nova. It had not given me personal control of the patents. It had done one precise thing: stopped Sterling from relying on the old permission while the required conditions remained unresolved.
Northstar's summary treated that condition as if it did not exist.
Julian joined the call from Mercer, but he did not offer to contact Northstar for me.
"Their diligence team will have a rights schedule," he said. "If the schedule is complete, they know about the suspension. If it is not, this warranty is sitting on an omission."
"Mercer does nothing with the information," I said.
"Agreed."
Northstar was a rival transaction party, not a weapon for Julian to use. Any correction would come from the Trust, the inventor record, and formal service.
Sterling's public employee message arrived next. Celeste called the merger proof that the market trusted her leadership. Conrad called it the protection of Helena's legacy. Nathan wrote that legal review had confirmed the company possessed the rights required to proceed.
That final sentence carried his title beneath it.
Chief Legal Officer.
Five years ago, Nathan could still claim that he had relied on internal accounts of who created the platform. The independent determination had removed that uncertainty. The license suspension existed in a dated Trust record. The new warranty had been made after both events.
Still, a public date was not the same as proof that Nathan had personally received every omitted document before he signed. I would not replace their exaggeration with mine.
"We serve the complete set," I told Rhea. "Northstar, Sterling, the transaction agent, and Nathan in his corporate capacity."
"With receipts."
"With receipts."
I looked once more at the seven-billion-dollar number filling the screen.
Sterling had announced it as pressure: too large to question, too important to delay, too close to completion to correct.
Helena's last letter remained beside me in its archival sleeve.
Choose by evidence rather than longing.
The announcement had not changed the evidence. It had only given nine directors, a new counterparty, and an entire market a reason to decide whether the evidence mattered.
I closed the celebration pages and saved the warranty.
Seven billion dollars had not made the rights complete.
It had only made the false sentence more expensive.